NYSE:ABBV - AbbVie Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$79.99 -0.53 (-0.66 %)
(As of 02/20/2019 04:00 PM ET)
Previous Close$80.52
Today's Range$79.14 - $80.60
52-Week Range$75.77 - $122.00
Volume5.56 million shs
Average Volume7.59 million shs
Market Capitalization$120.32 billion
P/E Ratio10.11
Dividend Yield5.32%
Beta1.17
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers. AbbVie Inc. has collaborations with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer – Commercialization of Research; the Université de Montréal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; Bristol-Myers Squibb Company; Voluntis; and Tizona Therapeutics, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.75 billion
Cash Flow$6.5138 per share
Book Value$3.19 per share

Profitability

Net Income$5.69 billion

Miscellaneous

Employees29,000
Outstanding Shares1,504,216,000
Market Cap$120.32 billion
OptionableOptionable

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Monday, November 5th. Stockholders of record on Tuesday, January 15th will be paid a dividend of $1.07 per share on Friday, February 15th. This represents a $4.28 annualized dividend and a dividend yield of 5.35%. The ex-dividend date of this dividend is Monday, January 14th. This is a positive change from AbbVie's previous quarterly dividend of $0.96. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie declared that its Board of Directors has authorized a stock buyback plan on Thursday, December 13th 2018, which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 3.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) released its quarterly earnings data on Friday, January, 25th. The company reported $1.90 EPS for the quarter, missing the consensus estimate of $1.92 by $0.02. The company earned $8.31 billion during the quarter, compared to analysts' expectations of $8.37 billion. AbbVie had a net margin of 17.36% and a negative return on equity of 1,343.27%. The firm's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.48 earnings per share. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY19 earnings guidance on Friday, January, 25th. The company provided earnings per share guidance of $8.65-8.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.72. AbbVie also updated its FY 2019 guidance to $8.65-8.75 EPS.

What price target have analysts set for ABBV?

17 equities research analysts have issued twelve-month price objectives for AbbVie's stock. Their forecasts range from $65.61 to $135.00. On average, they anticipate AbbVie's stock price to reach $94.0871 in the next year. This suggests a possible upside of 17.6% from the stock's current price. View Analyst Price Targets for AbbVie.

What is the consensus analysts' recommendation for AbbVie?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 4 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Has AbbVie been receiving favorable news coverage?

Headlines about ABBV stock have been trending neutral recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AbbVie earned a news impact score of 0.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near future.

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Mr. Carlos Alban, Vice Chairman & Chief Commercial Officer (Age 56)
  • Mr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman and External Affairs & Chief Legal Officer (Age 56)

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.37%), Northern Trust Corp (1.40%), Geode Capital Management LLC (1.17%), Bank of New York Mellon Corp (1.06%), Oregon Public Employees Retirement Fund (1.01%) and Legal & General Group Plc (0.49%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Dimensional Fund Advisors LP, First American Bank, Assenagon Asset Management S.A., First Trust Advisors LP, Brandywine Global Investment Management LLC, King Luther Capital Management Corp and HM Payson & Co.. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Vaughan Nelson Investment Management L.P., Bessemer Group Inc., Geode Capital Management LLC, Mn Services Vermogensbeheer B.V., Amundi Pioneer Asset Management Inc., APG Asset Management N.V. and Legal & General Group Plc. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $79.99.

How big of a company is AbbVie?

AbbVie has a market capitalization of $120.32 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is http://www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  871 (Vote Outperform)
Underperform Votes:  558 (Vote Underperform)
Total Votes:  1,429
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Featured Article: Balanced Fund

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel